CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
Sign Up to like & getrecommendations! Published in 2022 at "Cell Discovery"
DOI: 10.1038/s41421-021-00370-2
Abstract: Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting… read more here.
Keywords: sars cov; peptide vaccine; covac501; covac501 self ... See more keywords